Lynch syndrome is caused by germline mutations of DNA mismatch repair (MMR) genes. MMR deficiency has long been regarded as a secondary event in the pathogenesis of Lynch syndrome colorectal cancers. Recently, this concept has been challenged by the discovery of MMR-deficient crypt foci in the normal mucosa. We aimed to reconstruct colorectal carcinogenesis in Lynch syndrome by collecting molecular and histology evidence from Lynch syndrome adenomas and carcinomas. We determined the frequency of MMR deficiency in adenomas from Lynch syndrome mutation carriers by immunohistochemistry and by systematic literature analysis. To trace back the pathways of pathogenesis, histological growth patterns and mutational signatures were analyzed in Lynch syndrome colorectal cancers. Literature and immunohistochemistry analysis demonstrated MMR deficiency in 491 (76.7%) out of 640 adenomas (95% CI: 73.3% to 79.8%) from Lynch syndrome mutation carriers. Histologically normal MMR-deficient crypts were found directly adjacent to dysplastic adenoma tissue, proving their role as tumor precursors in Lynch syndrome. Accordingly, mutation signature analysis in Lynch colorectal cancers revealed that KRAS and APC mutations commonly occur after the onset of MMR deficiency. Tumors lacking evidence of polypous growth frequently presented with CTNNB1 and TP53 mutations. Our findings demonstrate that Lynch syndrome colorectal cancers can develop through three pathways, with MMR deficiency commonly representing an early and possibly initiating event. This underlines that targeting MMR-deficient cells by chemoprevention or vaccines against MMR deficiency-induced frameshift peptide neoantigens holds promise for tumor prevention in Lynch syndrome.
Lynch syndrome is caused by germline mutations of DNA mismatch repair (MMR) genes. MMR deficiency has long been regarded as a secondary event in the pathogenesis of Lynch syndrome colorectal cancers. Recently, this concept has been challenged by the discovery of MMR-deficient crypt foci in the normal mucosa. We aimed to reconstruct colorectal carcinogenesis in Lynch syndrome by collecting molecular and histology evidence from Lynch syndrome adenomas and carcinomas. We determined the frequency of MMR deficiency in adenomas from Lynch syndrome mutation carriers by immunohistochemistry and by systematic literature analysis. To trace back the pathways of pathogenesis, histological growth patterns and mutational signatures were analyzed in Lynch syndrome colorectal cancers. Literature and immunohistochemistry analysis demonstrated MMR deficiency in 491 (76.7%) out of 640 adenomas (95% CI: 73.3% to 79.8%) from Lynch syndrome mutation carriers. Histologically normal MMR-deficient crypts were found directly adjacent to dysplastic adenoma tissue, proving their role as tumor precursors in Lynch syndrome. Accordingly, mutation signature analysis in Lynch colorectal cancers revealed that KRAS and APC mutations commonly occur after the onset of MMR deficiency. Tumors lacking evidence of polypous growth frequently presented with CTNNB1 and TP53 mutations. Our findings demonstrate that Lynch syndrome colorectal cancers can develop through three pathways, with MMR deficiency commonly representing an early and possibly initiating event. This underlines that targeting MMR-deficient cells by chemoprevention or vaccines against MMR deficiency-induced frameshift peptide neoantigens holds promise for tumor prevention in Lynch syndrome.
Lynch syndrome and familial adenomatous polyposis (FAP) are two major inherited tumor syndromes predisposing to colorectal cancer. 1 FAP is inherited through a germline mutation in the APC gene, which, upon a second somatic hit, results in the formation of hundreds to thousands of adenomatous polyps (polyposis) in the colonic mucosa of mutation carriers. 2 The multiple clinically detectable lesions illustrate that APC germline mutations lead to a strong increase of the adenoma initiation rate in the colorectum. 2, 3 In contrast to FAP, polyposis is absent in Lynch syndrome, the most common hereditary colorectal cancer syndrome in adults, which is caused by germline mutations of DNA mismatch repair (MMR) genes. 4, 5 Although some studies found an increased adenoma incidence in Lynch syndrome mutation carriers, adenomatous polyps in Lynch syndrome were only slightly more prevalent than in the unaffected population. 6, 7 This observation has suggested that secondary event, and somatic mutations of MMR genes were thought to occur after the formation of polyps that had been caused by APC mutations or other events occurring independently from MMR deficiency.
Various observations of Lynch syndrome pathogenesis have been interpreted as supportive of this concept: these include the existence of polyps with retained or partial expression of MMR proteins 9 found in some Lynch syndrome patients. [10] [11] [12] Moreover, correlation of MMR deficiency with the higher grade and bigger size of the adenomas seemed to further corroborate the role of MMR deficiency as a "noninitiating" event in Lynch syndrome-associated colorectal carcinomas. 7, 9, 11, [13] [14] [15] In recent years, however, the classical view of Lynch syndrome as an "accelerating" disease has been challenged, most importantly by the discovery of MMR-deficient crypt foci (MMR-DCF), colonic crypts presenting with a normal histological appearance but already lacking the expression of MMR proteins. 10, 16 Although it has not been clear whether these MMR-DCF had the potential of being true cancer precursors, it demonstrated that MMR deficiency can strike in phenotypically normal cells and it in fact does so very frequently during the life of Lynch syndrome mutation carriers. 16 This observation opened up the possibility that MMR-deficient colorectal cancers in Lynch syndrome, at least to a certain proportion, may also develop from such MMR-DCF. This concept has also been supported by several observations in path_MMR gene variant carriers: The majority of adenomas show complete and homogeneous lack of MMR protein expression in all dysplastic cells, 17 50% of MMRdeficient adenomas smaller than 5 mm have high grade dysplasia, 14 and some MMR-DCF have aberrant histology, 18 pointing to their potential role as cancer precursors. Very recently, molecular studies on Lynch syndrome-associated colorectal cancers have provided further support for MMR deficiency as an event commonly preceding adenoma formation.
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These conflicting observations could be explained by the existence of multiple, common pathways of colorectal tumorigenesis in Lynch syndrome whereby MMR deficiency can either precede or follow adenoma formation. Furthermore, an entirely different pathway of carcinogenesis has been described that may bypass the formation of polyps and lead to the formation of invasive cancers from MMR-DCF through a nonpolypous progression pathway. 20 The existence This illustrates that the sequence of mutational events in Lynch syndrome carcinogenesis, which still represents a highly controversial topic, is of crucial relevance to the optimal clinical management of these patients. In addition to the single putative pathway in which MMR deficiency is a secondary, accelerating event, we hypothesized that two more common pathways can contribute to Lynch colorectal pathogenesis. These pathways are both initiated by nonpolypous and MMR-deficient precursor lesions that can either develop into polypous adenocarcinoma or invade directly into the colorectal wall. Therefore, we aimed to reconstruct the sequence of somatic mutational events in Lynch syndrome carcinogenesis from two perspectives. First, we performed a systematic literature review to determine the proportion of MMR-deficient adenomas in Lynch syndrome mutation carriers, complemented by the analysis of our own collection of adenoma samples. Second, we evaluated nextgeneration sequencing data of Lynch syndrome-associated colorectal cancers to detect mutational signatures reflecting the sequence of mutational events 23 and to identify fingerprints indicative of polypous or nonpolypous growth.
Materials and Methods

Patients and tumor specimens
Formalin-fixed paraffin-embedded tissue sections of 21 dysplastic adenomas from 15 Lynch syndrome mutation carriers participating in the CAPP2 trial (colorectal adenoma/carcinoma prevention programme 2, path_MLH1 variant carriers, n 5 10; path_MSH2 variant carriers, n 5 5) were retrieved and available for the analysis of MMR protein expression. The collection of tumors has been described in a previous study reporting the prevalence of polyps in Lynch syndrome mutation carriers. Formalin-fixed, paraffin-embedded archival tissue blocks from 21 carcinomas from Lynch syndrome mutation carriers (path_MLH1, n 5 9, path_MSH2, n 5 8, path_MSH6, n 5 3, path_PMS2, n 5 1) were obtained from the Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg. All patients provided their informed and written consent in frame of the German HNPCC Consortium, which was approved by the Institutional Ethics Committee.
Literature survey
The systematic literature search of studies listed in NCBI Pubmed by May 15, 2017 (2) from Lynch syndrome patients (3) using immunohistochemical staining of MMR proteins and/or PCR fragment length analysis of mononucleotide microsatellite markers were collected and used for integrated data analysis. Adenomas were included as "Lynch syndrome adenomas" if the described patients fulfilled the following criteria: proven path_MMR gene variant carrier OR history of a tumor showing loss of MMR protein expression plus proven path_MMR gene variant carrier among first-or second-degree relatives. Only adenomas classified as "dysplastic" were included in the calculation of the proportion of MMR-deficient lesions. The lesions were considered as MMR-deficient if they presented with MMR protein expression loss, instability of >30% of tested markers or both. Studies analyzing <20 lesions from Lynch syndrome patients were excluded. Collection of articles and extraction of data was performed by one author (AA) and verified by a second author (MK).
Immunohistochemistry (IHC)
For detection of MMR protein expression, paraffin blocks were cut into 3-mm-thick sections. Deparaffinization and tissue staining were performed according to standard protocols published previously. 25 The following primary antibodies were used: anti-MLH1 (clone G168-15, dilution 1:300, BD Pharmingen, Heidelberg, Germany) or anti-MSH2 (clone FE11, dilution 1:100, Calbiochem, Darmstadt, Germany), depending on the germline mutation status of the respective patient. Staining was visualized using the Vectastain elite ABC detection system (Vector, Burlingame, Calif., USA) and using 3,3 0 -Diaminobenzidine (DAB) (Dako) as chromogen.
Hematoxylin was used for blue counterstaining of cell nuclei. Cells with nuclear staining signals in MMR protein staining were assessed as MMR-proficient.
Mutational analysis of TCGA and DFCI databases TCGA 26 and DFCI 27 databases were used to determine somatic mutation patterns of commonly mutated colon cancer genes APC and KRAS in microsatellite-unstable (MSI) cancer samples (www.cbioportal.org, status: January 31, 2017)). 28, 29 Mutational and clinical data (including MSI typing and CIMP/MLH1 methylation status) were downloaded and used for stratification of MSI-H, MSI-L and MSS cancers. For the present study, MSI-L cancers were grouped together with MSS cancers and comprised together the "MSS" group, whereas "MSI-H" cancers are further referred to as "MSI" throughout the manuscript. MSI cancers with a negative CIMP/MLH1 methylation status were classified as "MSI Lynch" and evaluated together with our own cohort of 21 tumors from Lynch syndrome patients, from which APC and KRAS mutation data were obtained through next generation panel sequencing. MSI cancers with positive CIMP/ MLH1 methylation status were classified as "MSI sporadic" and evaluated separately. Samples without mutational data or without clinical data containing results of MSI typing were excluded.
The order of mutational events in MSI Lynch colorectal cancers was explored using the relative frequency of mutations in APC and KRAS and the association of these mutations with MMR deficiency, including insertion and deletion mutations at homopolymers and substitutions. Substitutions were typed according to the flanking nucleotide bases as well as the base transition or transversion, according to the scheme used by Alexandrov et al. 23 The substitution probabilities of mutational signature 6 (COSMIC) 23 were used to define expected frequencies of different substitutions in MMR-deficient colorectal cancer. To estimate the proportion of Lynch syndrome colorectal cancers in which MMR deficiency preceded APC mutation, APC mutations were classified as "MMR deficiency-related" if they were single nucleotide insertions or deletions affecting homopolymer sequences (mononucleotide repeats) or if they were C > T mutations occurring in a CpG sequence context, following a simplified approach based on mutational signatures. 23 Other mutations were classified as "MMR deficiency-unrelated."
Library preparation and semiconductor sequencing
Targeted next generation sequencing of 21 Lynch syndromeassociated colorectal cancers was performed on IonTorrent PGM and Proton sequencers using a custom 180 amplicon panel (CRC panel) encompassing mutation HotSpot regions in 30 genes 30 (Supporting Information, Table 2 ). Briefly, amplicon library preparation was performed with the Ion AmpliSeq Library Kit v2.0 using approximately 10 ng of DNA. The DNA was mixed with the primer pool, containing all primers for generating the 180 amplicons and the AmpliSeq HiFi Master Mix and transferred to a PCR cycler (BioRad, Munich, Germany). After the end of the PCR reaction, primer end sequences were partially digested using FuPa reagent, followed by the ligation of barcoded sequencing adapters (Ion Xpress Barcode Adapters, Life Technologies). The final library was purified using AMPure XP magnetic beads (Beckman Coulter, Krefeld, Germany) and quantified using qPCR (Ion Library Quantitation Kit, Thermo Fisher Scientific, Waltham, USA) on a StepOnePlus qPCR machine (Thermo Fisher Scientific, Waltham, USA). The individual libraries were diluted to a final concentration of 100 PM, pooled and processed to library amplification on an Ion OneTouch2. Unenriched libraries were qualitycontrolled using Ion Sphere quality control measurement on a QuBit instrument. After library enrichment (Ion OneTouch ES), the library was processed for sequencing using the Ion Torrent 200 bp HiQ sequencing chemistry and the barcoded libraries were loaded onto 318 or PI chips.
Variant calling and annotation
Data analysis was performed using the Ion Torrent Suite Software (version 5.0). After base calling, the reads were aligned against the human genome (hg19) using the TMAP algorithm within the Torrent Suite. Variant calling was performed with the variant caller plugin within the Torrent Suite Software and the IonReporter package using a corresponding bed-file containing the coordinates of the amplified regions. Only variants with an allele frequency >5% and minimum coverage >100 reads were taken into account. Variant annotation was performed using Annovar. 31 Annotations included information about nucleotide and amino acid changes of RefSeq annotated genes, COSMIC and dbSNP entries as well as detection of possible splice site mutations. For data interpretation and verification, the aligned reads were visualised using the IGV browser (Broad Institute). 32 
Statistical analysis
The calculation of 95% confidence intervals (CI) for the observed frequencies of MMR deficiency in Lynch syndrome adenomas was performed using the modified Wald method and GraphPad Prism software (Version 6.02). Fisher's exact test was performed to test for significant differences of mutation frequencies between groups, using GraphPad Prism software (Version 6.02). Median regression and Kernel density estimation of residuals was used in R (Version 3.3.1) to analyse the relationship between the relative frequencies of observed substitutions and their relative probabilities in mutational signature 6. 23 
Results
MMR deficiency in Lynch syndrome adenomas
To determine the frequency of DNA mismatch repair deficiency in adenomas from Lynch syndrome mutation carriers, we performed a systematic literature analysis. The initial search of the NCBI Pubmed database resulted in 545 records.
Five hundred and nine publications that evidently did not address the research topic of interest were excluded based on the title. Out of the remaining 36 records, 22 were excluded because they either did not address the research question or information on MMR deficiency could not be extracted systematically for the analyzed samples. An additional 2 studies were excluded because the number of the analyzed samples was too low (Fig. 1a) . The 12 studies that fulfilled the inclusion criteria reported information about MMR deficiency in dysplastic adenomas, with the number of samples studied ranging from 25 to 134. In total, 619 Lynch syndromeassociated dysplastic adenomas were included in the quantitative data synthesis for the calculation of the mean frequency of MMR deficiency in Lynch syndrome-associated adenomas. 7 out of 12 published studies used both IHC and PCR methods to determine MMR deficiency, 4 studies used only IHC and 1 study used only PCR-based methods (Fig.  1b) . In studies that used both methods, lesions were classified as MMR-deficient if at least one of the methods showed evidence of MMR deficiency. In total, evidence of MMR deficiency was detected in 472 out of 619 adenomas, with a slightly higher proportion of MMR-deficient lesions in cohorts analyzed by IHC compared to PCR-based methods (76.41% vs 69.02%, p 5 0.017).
In addition to the published series of dysplastic adenomas, we performed immunohistochemical staining of MMR proteins in 21 dysplastic adenoma specimens obtained during the CAPP2 trial (Supporting Information, Table 1 , Fig. 2 ). No significant difference in the proportion of MMR-deficient lesions was observed among lesions from patients taking aspirin and those taking placebo (8 of 10 in the aspirin vs 11/11 in the placebo group, p 5 0.214). These adenomas were then included in the quantitative data synthesis, constituting a final set of 640 dysplastic adenomas with confirmed MMR deficiency status. Overall, 491 (76.7%) out of these 640 examined lesions showed evidence of MMR deficiency (95% CI: 73.3-79.8%) (Fig. 1c Forest Plot) .
Information about heterogeneity of MMR protein expression in Lynch syndrome adenomas, that is, the existence of MMR-proficient dysplastic crypts, can provide important information about the sequence of mutation events in the respective lesion. Among the identified publications, explicit information about heterogeneity was available for 219 dysplastic adenomas that presented with MMR protein loss. 11, 12, 17 In addition, all 19 MMR-deficient adenomas from the CAPP2 cohort were analyzed for heterogeneity. Altogether, eight (3.3%) of these 238 adenomas showed MMRproficient dysplastic crypts. Single adenomas with a heterogeneous MMR protein expression pattern have also been reported in manuscripts not included in the quantitative data synthesis. 10, 33 Whereas onset of MMR deficiency occurring in an already existing adenoma may manifest as heterogeneity among dysplastic crypts, MMR deficiency preceding adenoma formation may be detectable through the presence of adjacent, nondysplastic MMR-DCF. 16 In fact, one of the MMRdeficient adenomas analyzed showed such MMR-deficient nondysplastic crypts (Fig. 2a) , indicating that MMR deficiency in this lesion occurred prior to adenoma formation.
Mutation patterns in Lynch syndrome cancers
Although giving a useful hint regarding the possible sequence of mutational events, examination of adenomas does not provide any information about tumor progression to cancer. To estimate the timing of MMR deficiency in Lynch syndrome associated colorectal cancers, we analyzed the frequencies of known driver mutations that are likely related to MMR deficiency to reconstruct the sequence of mutational events in relation to the onset of MMR deficiency.
The focus of this analysis was on mutations of genes playing a key role in the adenoma-carcinoma model of colorectal cancer, APC, KRAS and TP53. 8, 34 The analyzed mutations included small insertions and deletions and base substitutions. Mutational signature 6 from the COSMIC database, 23 which is associated with MMR deficient colorectal cancer, was used as a reference. We hypothesized that the observed mutations would be associated with this signature if MMR deficiency preceded their occurrence. We supplemented the next generation sequencing data of our collection of Lynch syndrome colorectal cancers (n 5 21) with data available in the TCGA and DFCI databases, from which mutation data of a total of 752 colorectal cancers samples ("MSI Lynch," n 5 26) could be included, resulting in a series of 47 colorectal cancers classified as "MSI Lynch" (Supporting Information, Fig. 1 ).
For TP53, which is known to be rarely mutated in Lynch syndrome colorectal cancers, 35 the number of mutation events in Lynch syndrome cancers was too low for a reliable analysis. Therefore we first examined mutations of the KRAS gene, which are considered a late event commonly occurring after the initiation of carcinogenesis 36 and therefore likely to occur after the onset of MMR deficiency. Oncogenic KRAS mutations most commonly affect codons 12 and 13 leading to loss of GTPase activity and in turn constitutive activation of the KRAS protein. 37 In total, 8 different types of substitution (determined by the base substitution and the context of flanking nucleotides) were identified in the analyzed colorectal cancers (Fig. 3a) . The relative frequencies of point mutation types in the KRAS gene observed in MSI Lynch colorectal cancers were linearly related to their relative probabilities in mutational signature 6 using quantile regression (b 5 0.752, p 5 0.033). However, KRAS mutations in MSS colorectal cancers were not linearly related to their relative probabilities in signature 6 (b 5 0.325, p 5 0.674). These findings suggest that KRAS gene mutations in Lynch syndrome cancers commonly occur after the onset of MMR deficiency (Fig. 3a) .
In contrast to the codon restriction of KRAS mutations, mutations of the APC tumor suppressor gene are more widespread over the entire gene sequence. Small insertion/deletion mutations at homopolymers and substitutions were observed in both, MSI Lynch and MSS colorectal cancers, but in different proportions. Single base pair insertion/deletions at homopolymers are strongly associated with MMR deficiency and mutational signature 6, and accounted for 16.7% of APC mutations in Lynch syndrome colorectal cancers, but only 5.0% of APC mutations in MSS colorectal cancers (Fisher's exact test, p 5 0.012). As for KRAS, the relative frequency of APC substitutions were linearly related to their relative probabilities from mutational signature 6 in MSI Lynch colorectal cancers (b 5 1.16, p < 0.001) but not in MSS colorectal cancers (b 5 0.494, p 5 0.336, Fig. 3b) .
As a rough approximation of the proportion of tumors that acquire MMR deficiency before APC mutation, the observed mutations were grouped into MMR deficiencyrelated and MMR deficiency-unrelated. Among Lynch syndrome cancers (n 5 47), 27 (75%) out of the total 36 APC mutation events were considered as MMR deficiency-related, being C > T mutations at CpG sites (n 5 21) or single nucleotide insertion/deletions at homopolymer sequences (n 5 6), whereas this was the case only in 209 (35%) out of 603 APC mutations in MSS cancers (Table 1) . Using the proportion of such mutations in MSS cancers as a background, we predicted the proportion of APC mutations occurring after the onset of MMR deficiency in hereditary MSI cancers to be 61% (95% CI: 33% to 80%) (Fig. 3c) , which is consistent with the proportion of adenomas with MMR deficiency. 
Nonpolypous cancers in Lynch syndrome: the third pathway
Previously, we have provided evidence that some Lynch syndrome-associated colorectal cancers develop through an adenoma-independent, nonpolypous pathway of progression. Such nonpolypous colorectal cancers were previously shown to frequently harbor CTNNB1 mutations as activators of Wnt signaling. 20 We now performed next generation sequencing to obtain a broader mutational pattern of such proposed nonpolypous Lynch syndrome colorectal cancers, identified by the absence of tumor-adjacent adenoma formations, and compared the mutation profile to cancers with evident adenoma history. As previously published, 20 CTNNB1 mutations predominantly occurred in cancers lacking evidence of an adenomatous precursor stage (5 out of 10 cancers, Fig. 4 ), but they were also found in one out of five cancers that developed in an adenoma. Significant differences between polypous and nonpolypous cancers with regard to mutations in colorectal cancer genes were only found for TP53 mutations (p 5 0.044, Fig. 4 ), which were restricted to cancers lacking evidence of polypous growth. The number of observed CTNNB1 mutations was too low to determine the (c) Estimation of the proportion of APC mutations occurring after MMR-deficiency based on a simplified approach using mutational signatures: MMR-deficiency-related APC mutations were detected in 27 out of 36 (75%) APC-mutant Lynch syndrome colorectal cancers. Assuming that only MMR-deficiency related mutations would be observed if all cancers had MMR deficiency preceding APC mutation and accounting for a background of 35% such mutations also occurring in MSS cancers, this number corresponds to 61% (95% CI: 33-80%) of MSI Lynch cancers having MMR loss precede APC mutation. timing of MMR deficiency. Two tumors lacking both, APC and CTNNB1 mutations harbored frameshift mutations of homopolymers in the RNF43 gene (not shown), an alternative activator of Wnt signaling.
Discussion
This study was initiated to comprehensively address the question of distinct pathogenesis pathways in Lynch syndrome on different levels, by analyzing colorectal lesions of different progression stages using literature data, molecular profiling and cancer genome databases. First, we examined the overall frequency of MMRproficient lesions among adenomas in Lynch syndrome mutation carriers by a systematic literature review, providing the largest dataset available so far. Literature data together with MMR deficiency data obtained in our own cohort revealed that MMR-proficient adenomas represent less than a quarter of all adenomas in Lynch syndrome (23.3%), indicating that the majority of Lynch syndrome adenomas are MMRdeficient. Naturally, most of the adenomas included in the literature analysis were from path_MLH1 and path_MSH2 carriers, and future analyses will have to show whether the proportion of MMR-deficient adenomas may be different in path_MSH6 and path_PMS2 carriers.
Overall, adenomas analyzed by IHC had a slightly, but significantly higher frequency of MMR deficiency than those analyzed by PCR. This is in contrast to the situation in MMR-deficient colorectal cancers, in which PCR-based methods have been shown to have a higher sensitivity. 38 This discrepancy likely reflects the fact that loss of protein expression occurs synchronously with the onset of MMR deficiency, whereas microsatellite instability gradually increases with the progression of MMR-deficient lesions, hence being less pronounced in adenomas compared to clinically diagnosed cancers. 39 In the present analysis, we therefore used IHC to detect MMR deficiency assuming it to have higher sensitivity than PCR-based techniques and to explore the spatial heterogeneity of MMR protein expression.
The vast majority of analyzed adenomas presented with a complete loss of the respective MMR protein, whereas adenomas presenting with heterogeneous MMR protein expression patterns in dysplastic crypts were absent in our own cohort, and reported only very rarely in the literature (3.3%). This observation can either be explained by MMR-deficient Figure 4 . Mutation status of key colorectal genes in Lynch syndrome cancers. Colorectal cancers were grouped according to the evidence of polypous growth (no, black; yes, grey; not assessable, white). (a) Patient-wise color-coded mutation data (red, stop mutation; orange, frameshift insertion/deletion mutation; purple, in-frame deletion; green, amino acid exchange activating oncogene; blue, amino acid exchange inactivating tumor suppressor gene). (b) Comparison of mutation frequencies between Lynch syndrome-associated colorectal cancers with and without evidence of polypous growth. A significantly higher mutation frequency was observed in nonpolypous than polypous cancers for TP53 (*p 5 0.044).
dysplastic cells very rapidly overgrowing MMR-proficient dysplastic cells, or alternatively by MMR deficiency preceding dysplasia formation. Compatible with the latter possibility, we detected nondysplastic MMR-deficient crypts directly adjacent to one dysplastic MMR-deficient adenoma from our own cohort, proving that MMR deficiency can be an initiating event in adenoma formation and that MMR-DCF are bona fide tumor precursors in Lynch syndrome.
To obtain a better estimate of the proportion of MSI colorectal cancer initiated by MMR deficiency, that is, MMR-DCF, and those originating from MMR-proficient adenomas, we reconstructed the sequence of events by determining whether APC and KRAS mutations in manifest cancers showed fingerprints of pre-existing MMR deficiency. It has recently been published that APC mutations in Lynch syndrome-associated colorectal cancers are more frequently insertion/deletion mutations at repetitive sequences than in microsatellite-stable colorectal cancers, 19 which agrees with our observations in this study. We extended the mutation signature analysis to include substitutions and showed that the relative frequencies of the observed APC substitutions were different in MSI Lynch and MSS colorectal cancers. Furthermore, the relative frequencies of each substitution in MSI Lynch colorectal cancers were similar to what would be expected if caused by MMR-deficiency, based on the probabilities determined by mutational signature 6, while this was not the case for MSS colorectal cancers, 23 adding further evidence that MMR deficiency frequently precedes APC mutation in Lynch syndrome-associated colorectal carcinogenesis. By classifying C > T transitions at CpG sites and insertion/ deletion mutations at repetitive sequences as "MMR deficiency-related," we predict that approximately 61% of APC mutations in Lynch syndrome-associated cancers occur after the onset of MMR deficiency. This observation is compatible with the hypothesis that the majority of adenomas ultimately developing into colorectal cancer in Lynch syndrome are initiated by MMR deficiency, in agreement with the high rate of MMR deficiency in adenomas, the existence of MMR-DCF and our unique finding of a MMR-deficient adenoma outgrowing from a MMR-DCF. Accounting for the fact that part of Lynch syndrome adenomas, instead of APC mutations, harbor MMR deficiency-induced RNF43 mutations as activators of Wnt/beta-catenin signaling, the percentage of adenomas initiated by MMR deficiency may even be higher than predicted from APC mutation signatures alone. 19, 40 Similarly the analysis of KRAS mutation patterns in MSI Lynch colorectal cancers revealed an association with the MMR-deficiency related mutational signature 6; as for APC, our data suggests a sequence of events in which MMR deficiency commonly precedes activating KRAS mutations. In addition, MMR deficiency being the cause of subsequent driver mutations is a likely explanation for the predominance of G13D mutations in MMR-deficient colorectal cancers as previously reported, 41 in spite of its potentially lower oncogenic effect compared to codon 12 mutations. 42 Our data also demonstrate the applicability of mutational signature analysis for tracking sporadic MSI cancer development. Also in these tumors, an elevated proportion of MMR deficiencyrelated APC mutations was observed. However, these results need to be integrated in carcinogenesis models that account for the different mutational events and precursor lesions, such as sessile serrated adenomas. 43 Our approach has limitations. First, we did an overall analysis of APC and KRAS mutations occurring in all tumors together, not dissecting individual tumors for the occurrence of multiple mutations. Second, due to lack of information about path_MMR gene variant status in tumors from DFCI/ TCGA databases, 26 tumors were assigned into the "MSI Lynch" group due to negative MLH1 promoter methylation/ CIMP status. This approach may lead to the inclusion of a small number of actually sporadic tumors, as two somatic mutations affecting both alleles of one MMR gene can lead to MMR deficiency in 20% of CIMP-negative MSI tumors. 44 We also assume a linear carcinogenesis model, not referring to the possibility of independent pathways of transformation developing in parts of the same tumor or precancerous lesion. Moreover, we cannot formally exclude the possibility that the increased proportion of MMR deficiencyrelated mutations observed in Lynch syndrome-associated cancers merely reflects an increased number of passenger mutations accumulating after transformation and the onset of MMR deficiency. However, the functional impact of the observed mutations and the fact that no increased load of randomly distributed, functionally irrelevant mutations was observed in oncogenes such as KRAS argues against the passenger mutation assumption and supports the validity of our conclusions.
Recent prospective studies on CRC incidence in Lynch syndrome patients under colonoscopic surveillance show that colorectal cancers occurred despite regular colonoscopy with polypectomy. 22, 45 Based on this observation, Møller et al.
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raised the question whether CRC in Lynch syndrome necessarily has to always emerge from a macroscopically visible lesion. Using panel sequencing, 46, 47 we examined the possibility that there is a distinct pathway reflected by a distinct molecular profile of the manifest cancers, which may support the concept that part of Lynch syndrome colorectal cancers may emerge from nonpolypous, that is, "invisible" precursor lesions. 20 Interestingly, a subset of MSI Lynch tumors presented with mutations of the TP53 gene, which are otherwise rare in MSI cancers. 35 All TP53-mutant tumors presented with a nonpolypous histology, suggesting that TP53 mutations, alongside CTNNB1 mutations, 20 may represent drivers of nonpolypous cancer formation in Lynch syndrome. On a mechanistic level, this observation is very well compatible with recent evidence that mutant gain-of-function variants of TP53 are associated with the formation of flat lesions and an inflammatory phenotype favoring invasive growth in murine models. 48 Clinically, our data support the existence of a distinct group of Lynch syndrome colorectal cancers that may manifest as interval cancers because they are not detectable even by high quality colonoscopy. 22, 45 Due to the limited number of tumors analyzed by panel sequencing, confirmation in independent tumor collections is strongly encouraged.
The contribution of nonpolypous cancers to the overall colorectal cancer burden in Lynch syndrome remains to be determined and most likely will vary between populations. In this context, it has to be kept in mind that the surveillance scheme applied in management of Lynch syndrome, which differs between countries, 22, 49 will most likely influence the picture significantly, because, as mentioned above, colonoscopy will, with a much higher likelihood detect, polypous adenomas compared to nonpolypous precursor lesions. Therefore, compared to a population not under regular colonoscopy, carcinomas developing through the nonpolypous tumorigenesis pathway will be much more frequent in populations participating in, for example, annual colonoscopy screening programs.
Due to low number of CTNNB1 and TP53 mutations, their timing with respect to MMR deficiency could not be reliably determined. However, CTNNB1 mutations are known to be associated with MSI cancers, 50 in particular with hereditary MSI CRC. 20, 51 It has also been shown that in colonic tissue CTNNB1 mutations alone are unable to drive activation of Wnt signaling. 52 Taken together with the high number of MMR-DCF in the normal colonic mucosa of Lynch syndrome patients, the scenario in which CTNNB1 strikes in an already MMR-deficient cell and leads to nonpolypous progression is much more likely than the reversed order of the events. However, studies need to be performed to determine the timing of mutations associated with nonpolypous growth in Lynch CRC.
In summary, the conflicting models of colorectal Lynch syndrome pathogenesis-MMR deficiency as a late event 3, 8, 53 versus MMR deficiency as an early event 17, 19, 20 -can only be reconciled by a unifying model that accepts the existence of distinct pathways of colorectal carcinogenesis in Lynch syndrome (Fig. 5) . Indeed, our study provides histological and molecular evidence that Lynch syndrome-associated colorectal cancers do not follow one single pathway, but three pathways separated from each other by the type and timing of key mutation events: colorectal cancers in Lynch syndrome can in fact grow out from MMR-proficient adenomas after secondary inactivation of the MMR system (pathway 1). However, a larger part of cancers appear to develop from precursor lesions in which MMR deficiency is an early event, likely to include MMR-DCF, either through an adenomatous phase (pathway 2) or as nonpolypous lesions with immediate invasive growth (pathway 3). Future studies will have to assess the relative contribution of each of these pathways to the colorectal cancer burden in Lynch syndrome, the effectiveness of screening programs to prevent each of these cancer types and the impact of the pathogenesis on patients' outcome and survival.
